

Results from 1069 IMRT irradiations of an anthropomorphic head and neck phantom

Andrea Molineu, Nadia Hernandez, Paola Alvarez, Geoffrey Ibbott, Jim Galvin and David Followill



Making Cancer History®




Once upon a time . . .






A family was made




And shipped around the world



IMRT H&N Phantom

- Primary PTV4 cm diameter4 TLD
- Secondary PTV2 cm diameter2 TLD
- Organ at risk1 cm diameter2 TLD
- Axial and sagittal radiochromic films




- •1° PTV treated to 6.6 Gy
- •2° PTV treated to 5.4 Gy
- •OAR limited to < 4.5 Gy

Designed in collaboration with RTOG; Molineu et al, IJROBP, October 2005



Criteria for credentialing

- RPC/Inst dose in PTVs: 0.93-1.07
- distance to agreement in high gradient region near OAR: ≤ 4 mm



IMRT H&N Phantom Results

- 1069 irradiations were analyzed
- •866 irradiations passed the criteria
- •203 irradiations did not pass the criteria
- 730 institutions are represented

81% of <u>irradiations</u> passed the criteria




IMRT H&N Phantom Results cont.

- 146 failed by absolute dose only
- 24 failed by DTA only
- 33 failed by both absolute dose and DTA


				% Pixels
	1PTV	2PTV	DTA (mm)	pass Gamma
mean	0.98	0.98	1.7	90
std dev	0.048	0.042	1.9	14
range	0.44 – 1.23	0.40 - 1.23	0 – 17	9 - 100




Gamma calculation



plan







gamma



Gamma calculation



plan




2
1.8
1.6
-1.4
-1.2
-1
-1
-0.8
-0.6
-0.4
-0.2

gamma



Gamma criteria proposal

- 85% of pixels pass
 7%/4mm gamma
- Use axial and sagittal films
- replace current DTA criteria



This is expected to decrease the current pass rate to around 75%



IMRT Technique

	Pass Rate (%)		Criteria Failed			
IMRT technique		Attempts	Dose	DTA	Dose and DTA	
Dynamic MLC	88	279	23	5	5	
IMAT	85	79	9	0	3	
Segmental	76	613	105	17	25	
Solid Attenuator	43	7	3	1	0	
TomoTherapy	92	91	6	1	0	
total		1069	146	24	33	



Linear Accelerator Manufacturer

Linear	Pass		Criteria Failed		
Accelerator Manufacturer	Rate (%)	Attempts	Dose	DTA	Dose and DTA
Elekta	67	115	32	4	2
Siemens	69	131	31	4	6
TomoTherapy	92	91	6	1	0
Varian	84	732	77	15	25
total		1069	146	24	33



Treatment Planning System

Treatment	Pass Rate (%)	Attempts	Criteria Failed			
planning system			Dose	DTA	Dose and DTA	
Eclipse	88	353	27	8	7	
Pinnacle	75	406	80	9	13	
TomoTherapy	92	91	6	1	0	
XiO	75	133	17	6	10	
Other	78	86	16	0	3	
total		1069	146	24	33	



Linear Accelerator and TPS

Linac/TPS	Pass	Attemp ts	Criteria Failed			
Combination	Rate (%)		Dose	DTA	Dose and DTA	
Elekta/Pinnacle	65	81	25	3	0	
Elekta/XiO	77	22	2	1	2	
Siemens/Pinnacle	66	73	21	0	4	
Siemens/XiO	70	37	6	3	2	
HiArt/TomoTherapy	92	91	6	1	0	
Varian/Eclipse	90	337	20	7	7	
Varian/Pinnacle	80	260	37	6	9	
Varian/XiO	77	74	9	2	6	



Tightened criteria—5%/4 mm

Treatment planning system	Pass Rate (%)
Eclipse	71
Pinnacle	55
TomoTherapy	78
XiO	53
Other	56

Failures double to 405



Conclusions

- Important QA tool
- Aids improvements to IMRT delivery
- All major linear accelerator and planning systems have ability to pass



Happily ever after . . .

The investigation was supported by PHS grants CA10953, CA81647 and CA21661 awarded by the NCI, DHHS.

